JAMA internal medicine
-
JAMA internal medicine · Jun 2018
Randomized Controlled Trial Comparative StudyWeekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations. ⋯ Compared with SL buprenorphine, depot buprenorphine did not result in an inferior likelihood of being a responder or having urine test results negative for opioids and produced superior results on the CDF of no illicit opioid use. These data suggest that depot buprenorphine is efficacious and may have advantages.